PMX-205
Also known as: C5aR antagonist PMX-205, hydrocinnamate-[OPdChaWR], PMX-205, PMX205
Source PMX-205 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
PMX‑205 is a synthetic peptide antagonist of the C5aR1 receptor used in preclinical models to attenuate inflammation, neurodegeneration, and sepsis‑related pathology.
Mechanism of Action
Competitive antagonist of complement component C5a receptor (C5aR1), blocking C5a‑mediated chemotaxis and pro‑inflammatory signaling
Routes of Administration
Goals & Uses
- Traumatic brain injury inflammationNeuroprotectionLow
- anti‑inflammatory therapyImmunomodulationModerate
- NeuroprotectionNeurologyModerate
- Inflammatory skin diseaseDermatology / Anti InflammatoryLow
- Sepsis mitigationInfectious DiseaseLow
- Complement-mediated inflammatory diseaseImmunomodulationLow
- Neuroinflammation reduction in Alzheimer's diseaseNeuroprotectionLow
Contraindications
- Known hypersensitivity to cyclic peptide componentsAllergyHigh
- Severe immunodeficiencyImmunologyModerate
Adverse Effects
- Injection site irritationLocal ReactionCommon
- Local irritation (topical)DermatologicalUnknown
- ImmunosuppressionImmunologicalUnknown
Drug Interactions
- Other complement inhibitors (e.g., eculizumab)Moderate
- Complement inhibitors (e.g., eculizumab)Moderate
Population Constraints
- Pediatric populationsAgeRelative
- pediatric subjectsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Immunocompromised individualsImmunologicalRelative
Regulatory Status
- European UnionUnapprovedResearch chemical only.
- United StatesUnapprovedInvestigational peptide; no IND filed for therapeutic use.
- United KingdomUnapprovedNo MHRA authorization; research use only.
Investigational research tool; not approved for clinical use in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is PMX-205?
PMX‑205 is a synthetic peptide antagonist of the C5aR1 receptor used in preclinical models to attenuate inflammation, neurodegeneration, and sepsis‑related pathology.
What is PMX-205 used for?
PMX-205 is educationally associated with: Traumatic brain injury inflammation, anti‑inflammatory therapy, Neuroprotection, Inflammatory skin disease, Sepsis mitigation, Complement-mediated inflammatory disease, Neuroinflammation reduction in Alzheimer's disease. Educational only — not medical advice.
How is PMX-205 administered?
Recorded routes of administration: Intracerebroventricular, Intracranial (research), Intraperitoneal, Intravenous, Subcutaneous, Topical.
What are the potential side effects of PMX-205?
Reported adverse effects include: Injection site irritation, Local irritation (topical), Immunosuppression. This list is not exhaustive — consult a qualified clinician.
Who should avoid PMX-205?
Recorded contraindications: Known hypersensitivity to cyclic peptide components, Severe immunodeficiency. Consult a qualified clinician before use.